9/16/2013 | BKDD | K-V Pharmaceutical exits bankruptcy with $375 million recapitalization
|
9/11/2013 | DD | K-V Pharmaceutical obtains OK of settlement with Florida, Ven-a-Care
|
8/29/2013 | DD | K-V Pharmaceutical's sixth amended joint reorganization plan confirmed
|
8/16/2013 | DD | K-V Pharmaceutical records $4.53 million of operating income for July
|
8/15/2013 | DD | K-V Pharmaceutical obtains court approval of Gedeon Richter settlement
|
8/14/2013 | DD | K-V Pharmaceutical eyes exclusivity extension ahead of plan hearing
|
8/13/2013 | DD | K-V Pharmaceutical, Florida and Ven-a-Care settle lawsuit and claim
|
7/24/2013 | DD | K-V Pharmaceutical, Gedeon ink settlement to resolve agreement issues
|
7/17/2013 | DD | K-V Pharmaceutical disclosure approved; plan hearing set for Aug. 28
|
7/16/2013 | DD | K-V Pharmaceutical reports $2.3 million of operating income for June
|
7/5/2013 | DD | K-V Pharmaceutical noteholders seek to subordinate convertible notes
|
6/20/2013 | DD | K-V Pharmaceutical's $3 million Texas Medicaid fraud settlement OK'd
|
6/17/2013 | DD | K-V Pharmaceutical reports $1.6 million of operating income for May
|
6/7/2013 | DD | K-V Pharmaceutical replacement financing, exclusivity extension OK'd
|
6/6/2013 | DD | K-V Pharmaceutical convertible noteholder group supports investor plan
|
5/30/2013 | DD | K-V Pharmaceutical delays hearing on financing, exclusivity extension
|
5/28/2013 | DD | K-V Pharmaceutical reaches $3 million Texas Medicaid fraud settlement
|
5/15/2013 | DD | K-V Pharmaceutical eyes exclusivity extension; proposal selection near
|
5/15/2013 | DD | K-V Pharmaceutical eyes exclusivity extension; proposal selection near
|
5/15/2013 | DD | K-V Pharmaceutical reports $1.57 million of operating income for April
|
5/8/2013 | DD | K-V Pharmaceutical lenders, noteholders ask to delay financing hearing
|
5/3/2013 | BKDD | K-V Pharmaceutical gets alternative plan proposal, DIP loan commitment
|
4/22/2013 | DD | K-V Pharmaceutical files second amended plan; statement hearing May 1
|
4/16/2013 | DD | K-V Pharmaceutical reports operating income of $1.76 million in March
|
4/12/2013 | DD | K-V Pharmaceutical creditors preparing equity financing commitment
|
3/19/2013 | DD | K-V Pharmaceutical submits amended plan; statement hearing April 23
|
3/15/2013 | DD | K-V Pharmaceutical operating income rises to $572,000 in February
|
2/28/2013 | DD | K-V Pharmaceutical creditors ask court to adjourn confirmation hearing
|
2/15/2013 | DD | K-V Pharmaceutical operating income declines to $127,000 in January
|
2/11/2013 | DD | Court: K-V Pharmaceutical noteholders do not have interest in Makena
|
2/5/2013 | DD | K-V Pharmaceutical secures exclusivity extension to negotiate plan
|
1/16/2013 | DD | K-V Pharmaceutical sees $1.46 million of operating income in December
|
1/10/2013 | DD | K-V Pharmaceutical seeks 120-day extension of plan exclusive periods
|
1/8/2013 | DD | K-V Pharmaceutical creditors claim noteholders have no Makena interest
|
1/8/2013 | DD | K-V Pharmaceutical submits plan based on senior noteholder agreement
|
12/31/2012 | DD | K-V Pharmaceutical wins approval of DIP financing, Hologic settlement
|
12/19/2012 | DD | K-V Pharmaceutical's creditors committee objects to proposed $60 million Hologic, Cytyc settlement
|
12/18/2012 | DD | K-V Pharmaceutical records $242,000 of operating income for November
|
12/13/2012 | CV | K-V Pharmaceutical, senior noteholders agree to Chapter 11 plan terms
|
12/13/2012 | DD | K-V Pharmaceutical, senior noteholders agree to Chapter 11 plan terms
|
12/12/2012 | DD | K-V Pharmaceutical requests approval of $85 million in DIP financing
|
12/12/2012 | DD | K-V Pharmaceutical to file reorganization plan for court confirmation
|
12/5/2012 | DD | K-V Pharmaceutical seeks approval of $60 million Hologic settlement
|
11/27/2012 | DD | K-V Pharmaceutical trustee raises questions regarding notes indenture
|
11/16/2012 | DD | K-V Pharmaceutical gets shorter exclusivity extension than requested
|
11/15/2012 | DD | K-V Pharmaceutical records $624,000 of operating income for October
|
11/7/2012 | DD | K-V Pharmaceutical creditor Hologic objects to exclusivity extension
|
10/26/2012 | DD | K-V Pharmaceutical seeks 90-day extension of exclusive plan periods
|
10/19/2012 | DD | K-V Pharmaceutical cash collateral extended to Nov. 21 from Oct. 18
|
10/16/2012 | DD | K-V Pharmaceutical operating loss narrows to $4 million in September
|
9/26/2012 | DD | K-V Pharmaceutical records $4.09 million operating loss for August
|
9/14/2012 | DD | K-V Pharmaceutical granted final approval of use of cash collateral
|
8/24/2012 | DD | K-V Pharmaceutical creditors committee object to cash collateral order
|
8/13/2012 | DD | K-V Pharmaceutical official unsecured creditors committee appointed
|
8/10/2012 | DD | Prospect News reports two new defaults for week of July 26 to Aug. 8
|
8/9/2012 | DD | K-V Pharmaceutical receives court approval for use of cash collateral
|
8/8/2012 | DD | K-V Pharmaceutical seeks approval of interim access to cash collateral
|
8/8/2012 | DD | K-V class A and B common shares trade on OTCQB after NYSE suspension
|
8/7/2012 | CV | Market Commentary: Existing Isis drops amid new deal, call; planned Isis price talk revised; Kodak falls
|
8/6/2012 | CVDDPV | K-V Pharmaceutical in bankruptcy to restructure financial obligations
|
7/2/2012 | DD | Market Commentary: Distressed debt action muted due to holiday; ATP heralds natural gas find, bonds hold steady
|
7/2/2012 | HY | Market Commentary: Junk primary quietly opens; Party City slates; deals hold gains; ATP, Rotech up on news
|
6/22/2012 | DD | Market Commentary: KV Pharma takes tumble as company struggles with Makena drug; ATP debt closes steady to softer
|
6/22/2012 | CV | Market Commentary: Patriot Coal continues to weaken; Onyx extends gains; Royal Gold slips in line; K-V drops
|
6/19/2012 | CV | Market Commentary: Revised price talk makes planned Affymetrix cheaper; DryShips expands; K-V Pharma drops
|
6/7/2012 | PP | K-V Pharmaceutical arranges $20 million equity line financing facility
|
2/10/2012 | CV | Market Commentary: Alcatel-Lucent up on strong earnings; Gilead, Amgen mixed on hedged basis; Siemens prices
|
6/17/2011 | CV | Market Commentary: Convertibles mostly soften; Clearwire down; China Sunergy offered at 52; KV Pharma active
|
6/17/2011 | HY | Market Commentary: Downstream, Evonik deals price to close out low-volume week; KV Pharma climbs on asset sale
|
5/4/2011 | DD | Market Commentary: Harrah's gains on loan change news; KV Pharma trading volatile; Catalyst slips, NewPage mixed
|
3/17/2011 | HYPV | New Issue: K-V Pharmaceutical prices upsized $225 million 12% four-year senior notes at 97
|
3/16/2011 | HY | Market Commentary: Lantheus prices, calendar thins, recent deals seen near issue; Japan still weighs on secondary
|
3/16/2011 | HYPV | New Issue: K-V Pharmaceutical sells $225 million 12% notes due 2015 at 97 in private placement
|
3/1/2011 | HYPV | K-V Pharmaceutical to offer $200 million notes via private placement
|
2/23/2011 | CV | Market Commentary: Convertibles under pressure; new Unisys wavers but adds dollar neutral; NetApp weaker
|
2/17/2011 | CV | Market Commentary: NetApp falls outright, flat on hedge; Allergan comes in slightly; KV Pharma extends gains
|
2/14/2011 | BKDD | K-V reaches agreement on amendment to facility size and structure
|
2/14/2011 | PP | KV Pharmaceutical negotiates $32.34 million private placement of stock
|
1/12/2011 | DD | Market Commentary: Distressed market stronger, still muted on new issues; Catalyst Paper jumps on redemption news
|
11/17/2010 | BKPPPV | K-V Pharmaceutical raises $60 million through loan, warrant financing
|
9/2/2009 | CV | Market Commentary: Alcatel-Lucent up on new issue; AMD a little weaker; Archer-Daniels-Midland adds; Beazer eyed
|
7/24/2009 | CVDD | K-V Pharmaceutical needs more capital; going concern status in doubt
|
12/31/2008 | SS | Deerfield Capital reports passive stake of 8.51% in KV Pharmaceutical
|
11/6/2006 | BT | KV Pharmaceuticals net revenues up 13% for second quarter of fiscal 2007, spurred by Ther-Rx
|
9/12/2006 | BT | KV Pharmaceutical gets FDA OK to sell generic Tiazac for hypertension
|
8/8/2006 | BT | KV Pharmaceuticals reports net revenues up 15% at $98.4 million for first quarter of fiscal 2007
|
6/14/2006 | BT | KV Pharmaceutical net revenues up 23% to $87.4 million
|
6/14/2006 | BT | KV Pharmaceutical gets $320 million revolver
|
6/14/2006 | BT | Market Commentary: KV Pharma up; Clinical Data, OccuLogix off; Advanced Magnetics spikes; Vasogen soars
|
3/29/2006 | BT | K-V Pharmaceutical takes out $43 million mortgage
|
2/14/2006 | BT | KV to market generic drugs in U.S. through deal with Gedeon
|
1/18/2006 | BT | KV Pharmaceutical, Andrx win summary judgment in patent litigation with AstraZeneca
|
1/18/2006 | BT | Market Commentary: KV Pharmaceutical stock up on patent ruling; biotech offerings take a back seat to tech market
|
5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
5/16/2003 | CV | KV Pharmaceutical greenshoe exercised, raising convertibles to $200 million
|
5/13/2003 | CV | New Issue: KV Pharmaceutical upsized $175 million convertibles yield 2.5%, up 37.5%
|
5/13/2003 | CV | Market Commentary: Many players welcome influx of new deals, though rich; hoping raging demand will be curbed
|
5/12/2003 | CV | KV Pharmaceutical $130 million overnighter talked to yield 2.25-2.75%, up 35-40%
|
5/12/2003 | CV | Market Commentary: Traders begin to boost hedges but note lack of conviction in rally; three new deals emerge
|